Market Research Logo

Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2018

Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2018 provides an overview of Dry Powder Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dry Powder Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Dry Powder Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Dry Powder Inhaler Devices Overview
3 Products under Development
3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory
3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials
4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies
4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
5 Dry Powder Inhaler Devices Companies and Product Overview
5.1 Acorda Therapeutics Inc Company Overview
5.2 Adamis Pharmaceuticals Corp Company Overview
5.3 Advent Pharmaceuticals Pty Ltd Company Overview
5.4 Aespira Ltd. Company Overview
5.5 AKELA Pharma Inc. (Inactive) Company Overview
5.6 AstraZeneca Plc Company Overview
5.7 Bayer AG Company Overview
5.8 Bespak Europe Ltd Company Overview
5.9 Boehringer Ingelheim GmbH Company Overview
5.10 Circassia Pharmaceuticals Plc Company Overview
5.11 GlaxoSmithKline Plc Company Overview
5.12 MannKind Corp Company Overview
5.13 Monash University Company Overview
5.14 Nanotherapeutics Inc (Inactive) Company Overview
5.15 Nektar Therapeutics Company Overview
5.16 OPKO Health Inc Company Overview
5.17 Pharmaxis Ltd Company Overview
5.18 Respira Therapeutics Inc Company Overview
5.19 Sandoz International GmbH Company Overview
5.20 Sheffield Hallam University Company Overview
5.21 Sun Pharma Advanced Research Company Ltd Company Overview
5.22 University of Kansas Company Overview
5.23 University of Texas Medical Branch at Galveston Company Overview
5.24 Vectura Group Plc Company Overview
5.25 Verona Pharma Plc Company Overview
5.26 Virginia Commonwealth University Company Overview
6 Dry Powder Inhaler Devices- Recent Developments
6.1 Jun 07, 2018: MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase
6.2 Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director
6.3 May 21, 2018: 3M forms sustainability and product stewardship organization
6.4 May 17, 2018: New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy as needed in mild asthma
6.5 May 16, 2018: Novartis announces changes to the Executive Committee
6.6 May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
6.7 May 10, 2018: Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
6.8 May 10, 2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018
6.9 May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director
6.10 May 09, 2018: 3M Announces New Leadership Appointment
6.11 May 09, 2018: MannKind Reports 2018 First Quarter Financial Results
6.12 May 09, 2018: Simon Dingemans, Chief Financial Officer, to retire from GSK
6.13 May 08, 2018: OPKO Health Announces First Quarter 2018 Financial Results
6.14 May 03, 2018: Teva Reports First Quarter 2018 Financial Results
6.15 May 01, 2018: OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories
6.16 Apr 26, 2018: Consort Medical: Director Declaration
6.17 Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
6.18 Apr 24, 2018: Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD
6.19 Apr 20, 2018: Vectura Announces Senior Management Change
6.20 Apr 20, 2018: Vectura Group: Directorate Change - Chief Financial Officer
6.21 Apr 19, 2018: Boehringer Ingelheim and HealthPrize Expand Successful Digital Patient Support Program
6.22 Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company
6.23 Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
6.24 Apr 18, 2018: Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD
6.25 Apr 18, 2018: GlaxoSmithKline Names Kevin Sin as new Senior Vice President and Head of Worldwide Business Development for Research & Development
6.26 Mar 29, 2018: Final results from landmark DYNAGITO trial published in The Lancet Respiratory Medicine
6.27 Mar 27, 2018: Construction Launch For New Chiesi Farmaceutici Headquarters
6.28 Mar 26, 2018: Acorda Files Marketing Authorization Application for INBRIJA (levodopa inhalation powder)
6.29 Mar 21, 2018: Vectura Group: 2017 Preliminary Results
6.30 Mar 21, 2018: Vectura Group: 2017 Preliminary Results - Performance in-line with expectations, with strong in-market growth from key inhaled products
6.31 Mar 20, 2018: Orion Board of Arrangement
6.32 Mar 19, 2018: Orion has Received Positive Conclusions for the Salmeterol-fluticasone Easyhaler Combination Under the EU''''s Decentralized Procedures
6.33 Mar 16, 2018: Asthma: Expanded indication for SPIRIVA Respimat for people 6 years and older
6.34 Mar 15, 2018: Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update
6.35 Mar 13, 2018: MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions
6.36 Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities
6.37 Mar 08, 2018: GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma
6.38 Mar 05, 2018: 3M Announces New Leadership Appointments
6.39 Mar 01, 2018: MannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension
6.40 Mar 01, 2018: OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results
6.41 Mar 01, 2018: Nektar Therapeutics Announces Fourth Quarter And Year-End 2017 Financial Results
6.42 Feb 27, 2018: MannKind Reports 2017 Fourth Quarter and Full Year Financial Results
6.43 Feb 23, 2018: GSK, Ministry of Economy, Trade and Industry Superior Health and Good Management Act 2018 (White 500) for 2 consecutive years certified
6.44 Feb 22, 2018: Treatment with Novartis Ultibro Breezhaler improved cardiac function in COPD patients with lung hyperinflation
6.45 Feb 20, 2018: Acorda Announces FDA Acceptance of New Drug Application for INBRIJA (levodopa inhalation powder)
6.46 Feb 20, 2018: Lexington Begins HeartSentry Clinical Trial
6.47 Feb 16, 2018: GSK Statement: GSK Voluntary Recall Of Ventolin Diskus Lot 786G In Canada
6.48 Feb 14, 2018: GSK submits landmark IMPACT data to European Medicines Agency to support expanded label for Trelegy Ellipta
6.49 Feb 13, 2018: BioLife Solutions Executes OEM Agreement with MilliporeSigma
6.50 Feb 12, 2018: Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole
6.51 Feb 09, 2018: Novartis layoffs to start in April at closing Broomfield plant
6.52 Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results
6.53 Feb 07, 2018: Orion Group Financial Statement Release for 2017
6.54 Feb 07, 2018: GSK delivers improvements in sales, margins and cash flow in 2017
6.55 Feb 06, 2018: MannKind Names David Kendall As Chief Medical Officer
6.56 Feb 06, 2018: Teva Pharmaceuticals laid off 46 employees in Parsippany
6.57 Jan 29, 2018: Novartis India Appoints Jawed Zia As Vice Chairman And Managing Director
6.58 Jan 26, 2018: GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma
6.59 Jan 26, 2018: OPKO Health Announces Resignation Of Gregory Henderson As President Of BioReference Laboratories
6.60 Jan 25, 2018: 3M Reports Fourth-Quarter 2017 Results; Raises 2018 Earnings Outlook
6.61 Jan 19, 2018: Teva Layoffs To Affect 65 Employees In Horsham, North Wales
6.62 Jan 10, 2018: Boehringer Ingelheim's Respimat Inhaler Awarded Arthritis Foundation's Ease of Use Commendation
6.63 Jan 09, 2018: Representative Director and President of GlaxoSmithKline Corporation Personnel notice
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Table 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
Table 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
Table 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
Table 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
Table 6: Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
Table 7: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Table 8: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: CVT-427 Drug Delivery Device - Product Status
Table 10: CVT-427 Drug Delivery Device - Product Description
Table 11: INBRIJA - Product Status
Table 12: INBRIJA - Product Description
Table 13: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 14: Taper DPI - Product Status
Table 15: Taper DPI - Product Description
Table 16: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 17: g60 Dry Powder Inhaler - Product Status
Table 18: g60 Dry Powder Inhaler - Product Description
Table 19: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 20: resQhaler - Product Status
Table 21: resQhaler - Product Description
Table 22: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Fentanyl TAIFUN Inhaler - Product Status
Table 24: Fentanyl TAIFUN Inhaler - Product Description
Table 25: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Duaklir Genuair Metered Dose Inhaler - Product Status
Table 27: Duaklir Genuair Metered Dose Inhaler - Product Description
Table 28: Bayer AG Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Ciprofloxacin Dry Powder Inhaler - Product Status
Table 30: Ciprofloxacin Dry Powder Inhaler - Product Description
Table 31: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 32: DEV610 DPI - Product Status
Table 33: DEV610 DPI - Product Description
Table 34: Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Next Generation Respimat Inhaler - Product Status
Table 36: Next Generation Respimat Inhaler - Product Description
Table 37: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Tiotropium bromide DPI - Product Status
Table 39: Tiotropium bromide DPI - Product Description
Table 40: GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Gemini Multi-Dose Combination Inhaler - Product Status
Table 42: Gemini Multi-Dose Combination Inhaler - Product Description
Table 43: MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 44: Dreamboat - Product Status
Table 45: Dreamboat - Product Description
Table 46: Treprostinil Technosphere - Product Status
Table 47: Treprostinil Technosphere - Product Description
Table 48: MannKind Corp - Ongoing Clinical Trials Overview
Table 49: Treprostinil Technosphere - Phase I Clinical Study of Treprostinil Technosphere (TreT) for Pulmonary Arterial Hypertension
Table 50: Monash University Pipeline Products & Ongoing Clinical Trials Overview
Table 51: Aerosol Delivery System - Product Status
Table 52: Aerosol Delivery System - Product Description
Table 53: Nanotherapeutics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 54: GelVac Intranasal Powder Vaccine Delivery System - Product Status
Table 55: GelVac Intranasal Powder Vaccine Delivery System - Product Description
Table 56: NanoGENT - Product Status
Table 57: NanoGENT - Product Description
Table 58: Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
Table 59: Nektar Dry Powder Inhaler - Amikacin - Product Status
Table 60: Nektar Dry Powder Inhaler - Amikacin - Product Description
Table 61: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 62: Inspiromatic - Product Status
Table 63: Inspiromatic - Product Description
Table 64: Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Orbital Dry Powder Inhaler - Product Status
Table 66: Orbital Dry Powder Inhaler - Product Description
Table 67: Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 68: RT234 AOS DPI - Product Status
Table 69: RT234 AOS DPI - Product Description
Table 70: Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 71: Solis Multi-Dose Dry Powder Inhaler - Product Status
Table 72: Solis Multi-Dose Dry Powder Inhaler - Product Description
Table 73: Unit-Dose Dry Powder Inhaler - Product Status
Table 74: Unit-Dose Dry Powder Inhaler - Product Description
Table 75: Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Dry Powder Inhaler - Product Status
Table 77: Dry Powder Inhaler - Product Description
Table 78: Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 79: SPARC DPI - Product Status
Table 80: SPARC DPI - Product Description
Table 81: University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
Table 82: Dry Powder Inhaler - Product Status
Table 83: Dry Powder Inhaler - Product Description
Table 84: University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
Table 85: Dry Powder Drug Delivery System - Product Status
Table 86: Dry Powder Drug Delivery System - Product Description
Table 87: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 88: Digitally - Connected LOMI Device - Product Status
Table 89: Digitally - Connected LOMI Device - Product Description
Table 90: SKP-2075 - Product Status
Table 91: SKP-2075 - Product Description
Table 92: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 93: RPL554 - Dry Powder Inhaler - Product Status
Table 94: RPL554 - Dry Powder Inhaler - Product Description
Table 95: Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
Table 96: Dry Powder Inhaler - Product Status
Table 97: Dry Powder Inhaler - Product Description
Table 98: Glossary
1.2 List of Figures
Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report